METTL3 and neoplasm: To further investigate the expression of METTL3, METTL14, WTAP and CBLL1 in PCa patients, IHC was carried out on a prostate TMA comprising non-malignant and tumour specimens (Figure 2) and subsequently correlated with clinicopathological parameters (Figure 3; Supplementary Table S2).